Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

NCT01542788 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: SOF
DRUG: RBV
DRUG: Placebo to match SOF
DRUG: Placebo to match RBV

Sponsor

Gilead Sciences